Serum amyloid a and its potential physiological/pathological functions - an overview of patents

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 4, Issue 2, 2010, Pages 89-99

  Lakota, Katja ^a   Mrak Poljsak, Katjusa ^a   Rozman, Blaz ^a   Sodin Semrl, Snezna ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Acute phase response; Homeostasis; Inflammation; Receptors; Serum amyloid A; TLR 2

Indexed keywords

ISOPROTEIN; SERUM AMYLOID A; SERUM AMYLOID A4; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ACIDOSIS; ACUTE GRAFT REJECTION; AMYLOIDOSIS; ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; GLAUCOMA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; INFECTION; INFLAMMATION; LUNG PARENCHYMA; MASTITIS; NONHUMAN; OBESITY; PATENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RHEUMATOID ARTHRITIS; URINARY TRACT INFECTION;

EID: 77953743340     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221410791196632     Document Type: Article

References (120)

1. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
2. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-23.
3. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: A prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996; 26: 427-35.
4. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: The National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-32.
5. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y, et al. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ J 2005; 69: 1186-91.
6. Dayer E, Dayer JM, Roux-Lombard P. Primer: The practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol 2007; 3: 512-20.
7. Malle E, Sodin-Semrl S, Kovacevic A. Serum amyloid A: An acute-phase protein involved in tumour pathogenesis. Cell Mol Life Sci 2009; 66: 9-26.
8. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998; 334: 489-503.
9. Sellar GC, Jordan SA, Bickmore WA, Fantes JA, van Heyningen V, Whitehead AS. The human serum amyloid A protein (SAA) superfamily gene cluster: Mapping to chromosome 11p15.1 by physical and genetic linkage analysis. Genomics 1994; 19: 221-7.
10. Kovacevic A, Hammer A, Stadelmeyer E, Windischhofer W, Sundl M, Ray A, et al. Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines. J Cell Biochem 2008; 103: 9941004.
11. Steel DM, Whitehead AS. The major acute phase reactants: Creactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994; 15: 81-8.
12. Faulkes DJ, Betts JC, Woo P. Characterization of five human serum amyloid A1 alleles. Amyloid Int J Exp Clin Invest 1994; 1: 255-62.
13. Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: the influence of SAA 1 genotypes and corticosteroid treatment in Japanese patients with rhematoid arthritis. Ann Rheum Dis 2001; 60: 124-7.
14. Stevens FJ. Hypothetical structure of human serum amyloid A protein. Amyloid 2004; 11: 71-80.
15. Sipe JD. Serum amyloid A: From fibril to function. Amyloid 2000; 7: 10-12.
16. Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001; 13: 67-73.
17. Upragarin N, Landman WJ, Gaastra W, Gruys E. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol 2005; 20: 1295-307.
18. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function. Proc Natl Acad Sci USA 1994; 91: 3186-90.
19. O'Hara R, Murphy EP, Whitehead AS, FitzGerald O, Bresnihan B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res 2000; 2: 142-4.
20. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, et al. Expression of serum Amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J Histochem Cytochem 2006; 54: 63-73.
21. Jiang SL, Lozanski G, Samols D, Kushner I. Induction of human serum amyloid A in Hep3B cells by IL-6 and IL-1 involves both transcriptional and posttranscriptional mechanisms. J Immunol 1995; 154: 825-31.
22. Uhlar CM, Whitehead AS. The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-1 and IL-6 is determined by the order of cytokine addition. Scand J Immunol 1999; 49: 399-404.
23. Patel H, Fellowes R, Coade S, Woo P. Human serum amyloid A has cytokine-like properties. Scand J Immunol 1998; 48: 410-8.
24. Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001; 166: 2801-7.
25. Liang JS, Sipe JD. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res 1995; 36: 37-47.
26. van der Westhuyzen DR, Cai L, de Beer MC, de Beer FC. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem 2005; 280: 35890-5.
27. Lowell CA, Stearman RS, Morrow JF. Transcriptional regulation of serum amyloid A gene expression. J Biol Chem 1986; 261: 8453-61.
28. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during acute-phase response. Biochem J 1998; 334: 489-503.
29. Mitchell TI, Jeffrey JJ, Palmiter RD, Brinckerhoff CE. The acute phase reactant serum amyloid A (SAA3) is a novel substrate for 98 degradation by the metalloproteinases collagenase and stromelysin. Biochim Biophys Acta 1993; 1156: 245-54.
30. Badolato R, Johnston JA, Wang JM, McVicar D, Xu LL, Oppenheim JJ, et al. Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol 1995; 155: 4004-10.
31. Su SB, Gong WH, Gao JL, Shen W, Murphy PM, Oppenheim JJ, et al. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med 1999; 189: 395-402.
32. Xu L, Badolato R, Murphy WJ, Longo DL, Anver M, Hale S, et al. A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J Immunol 1995; 155: 118490.
33. Olsson N, Siegbahn A, Nilsson G. Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxinsensitive signal transduction pathway. Biochem Biophys Res Commun 1999; 254: 143-6.
34. Jijon HB, Madsen KL, Walker JW, Allard B, Jobin C. Serum amyloid A activates NF-kappaB and proinflammatory gene expression in human and murine intestinal epithelial cells. Eur J Immunol 2005; 35: 718-26.
35. Furlaneto CJ, Campa A. A novel function of serum amyloid A: A potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem Biophys Res Commun 2000; 268: 405-8.
36. Sodin-Semrl S, Spagnolo A, Mikus R, Barbaro B, Varga J, Fiore S. Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int J Immunopathol Pharmacol 2004; 17: 145-56.
37. Walder K, Kantham L, McMillan JS, Trevaskis J, Kerr L, De Silva A, et al. Tanis: A link between type 2 diabetes and inflammation? Diabetes 2002; 51: 1859-66.
38. Cai L, de Beer MC, de Beer FC, van der Westhuyzen DR. Serum Amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 2005; 280: 2954-61.
39. Rocken C, Kientsch-Engel R, Mansfeld S, Stix B, Stubenrauch K, Weigle B, et al. Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis. Am J Pathol 2003; 162: 1213-20.
40. He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113: 429-37.
41. Cheng N, He R, Tian J, Ye PP, Ye RD. Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 2008; 181: 22-6.
42. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. The S100A8-serum amyloid A3TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10: 1349-55.
43. Whitehead, S.A. Methods for determining steroid responsiveness. US6878518 (2005).
44. Whitehead, S.A. Methods for determining drug responsiveness. US20090286267 (2009).
45. Whitehead, S.A. Methods for determining drug responsiveness. US20090286248 (2009).
46. Wild, N., Grunert, V.P., Karl, J., Zolg, W. Measurement of antiCCP and serum amyloid A method to assess rheumatoid arthritis. US20070298518 (2007).
47. Leske MC. The epidemiology of open angle glaucoma: A review. Am J Epidemiol 1983; 118: 166-91.
48. Vaughan D, Ashbury T, Tabbara KF. General Ophthalmology. Appleton & Lange, Norwalk: Conn 1992; 213-30.
49. Bengtsson BO. Incidence of manifest glaucoma. Br J Ophthalmol 1989; 73: 483-7.
50. Strong NP. How optometrists screen for glaucoma: A survey. Ophthalmic Physiol Opt 1992; 12: 3-7.
51. Clark, A.F., Wang, W.-H., McNatt, L. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents. US7357931 (2008).
52. Clark, A.F., Wang, W.H., McNatt, L.G. Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents. US20070208043 (2007).
53. Clark, A.F., Wang, W.H., McNatt, L. RNAi inhibition of serum amyloid A for treatment of glaucoma. US20060172961 (2006).
54. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: 85-151.
55. Cohen JD. A population-based approach to cholesterol control. Am J Med 1997; 102: 23-5.
56. Gotlieb AI, Benditt EP, Schwarz SM. Blood vessels. In: Rubin E, Farber JL, Eds. Pathology. Lippincott-Raven: Philadelphia, New York1999: 481-530.
57. Kisilevsky R, Tam SP. Acute phase serum amyloid A, cholesterol metabolism and cardiovascular disease. Pediatr Pathol Mol Med 2002; 21: 291-305.
58. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease -baseline findings of the PAIS project. Atherosclerosis 2001; 156: 451-6.
59. Kisilevsky R, Tam SP, Ancsin JB. The anti-atherogenic potential of serum amyloid A peptides. Curr Opin Invest Drugs 2008; 9: 26573.
60. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-24.
61. Wilson PG, Thompson JC, Webb NR, de Beer FC, King VL, Tannock LR. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am J Pathol 2008; 173: 1902-10.
62. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009; 14: 187-96.
63. Steinmetz A, Hocke G, Saïle R, Puchois P, Fruchart JC. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta 1989; 1006: 173-8.
64. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes proinflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-67.
65. Liang JS, Schreiber BM, Salmona M, Phillip G, Gonnerman WA, de Beer FC, et al. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J Lipid Res 1996; 37: 2109-16.
66. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 1992; 66: 778-85.
67. Banka CL, Yuan T, de Beer MC, Kindy M, Curtiss LK, de Beer FC. Serum amyloid A (SAA): Influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 1995; 36: 1058-65.
68. Liang JS, Sipe JD. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J Lipid Res 1995; 36: 37-46.
69. Kisilevsky R, Subrahmanyan L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab Invest 1992; 66: 778-85.
70. Erratum in: Lab Invest 1992; 67: 151.
71. Kisilevsky, R. Method of use of serum amyloid a protein. US6004936 (1999).
72. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999; 274: 7172-81.
73. Rocken C, Kisilevsky R. Comparison of the binding and endocytosis of high-density lipoprotein from healthy (HDL) and inflamed (HDL(SAA)) donors by murine macrophages of four different mouse strains. Virchows Arch 1998; 432: 547-55.
74. Marsche G, Frank S, Raynes JG, Kozarsky KF, Sattler W, Malle E. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. Biochem J 2007; 402: 117-24.
75. Ely S, Bonatesta R, Ancsin JB, Kindy M, Kisilevsky R. The in vitro influence of serum amyloid A isoforms on enzymes that regulate the balance between esterified and un-esterified cholesterol. Amyloid 2001; 8: 169-81.
76. Lindhorst E, Young D, Bagshaw W, Hyland M, Kisilevsky R. Acute inflammation, acute phase serum amyloid A and cholesterol metabolism in the mouse. Biochim Biophys Acta 1997; 1339: 14354.
77. Tam SP, Flexman A, Hulme J, Kisilevsky R. Promoting export of macrophage cholesterol: The physiological role of a major acutephase protein, serum amyloid A 2.1. J Lipid Res 2002; 43: 141020.
78. Kisilevsky, R. Amyloid precursor protein. US5318958 (1994).
79. Kisilevsky, R., Tam, S.P, Ancsin, J.B., Jia, Z. Compositions and methods for treating atherosclerosis. US7291590 (2007).
80. Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y, et al. Serum amyloid a protein as a predictor of cardiac rupture in acute myocardial infarction patients following primary coronary angioplasty. Circ J 2006; 70: 530-5.
81. Jackowski, G., Thatcher, B., Marshall, J., Yantha, J., Vrees, T. Biopolymer marker indicative of disease state having a molecular weight of 1525 Daltons. US7229638 (2007).
82. Fischer, T.J., Downey, C., Nesheim, M., Samis, J.A., Tejidor, L., Toh, C.H., Walker, J.B. Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality. US7179612 (2007).
83. Kitchens CS. Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). Hematol Am Soc Hematol Educ Prog 2009: 240-6.
84. Charlton, M.R. Serum biomarkers for early detection of acute cellular rejection. US20090088409 (2009).
85. Streeper, R.T, Izbicka, E., Baek, S.H. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues. US20090068685 (2009).
86. Ito, K., Gemma, N., Nakamura, N., Takahashi, M., Hashimoto, K. Nucleotide primer set and nucleotide probe for detecting genotype of serum amyloid A1(SAA1). US20090061433 (2009).
87. Sharif, N.A. Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balanc. US20090181893 (2009).
88. Walder K, Kantham L, McMillan JS, Trevaskis J, Kerr L, De Silva A, et al. Tanis: A link between type 2 diabetes and inflammation? Diabetes 2002; 51: 1859-66.
89. Karlsson HK, Tsuchida H, Lake S, Koistinen HA, Krook A. Relationship between serum amyloid A level and Tanis/SelS mRNA expression in skeletal muscle and adipose tissue from healthy and type 2 diabetic subjects. Diabetes 2004; 53: 1424-8.
90. Du JL, Sun CK, Lü B, Men LL, Yao JJ, An LJ, et al. Association of SelS mRNA expression in omental adipose tissue with Homa-IR and serum amyloid A in patients with type 2 diabetes mellitus. Chin Med J (Engl) 2008; 121: 1165-8.
91. Collier, G., Walder, K., Zimmet, P., Bayles, L. Modulating serum amyloid A interaction with tanis and agents useful for same. US20080039364 (2008).
92. Yang RZ, Lee MJ, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute-phase serum amyloid A: An inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med 2006; 3: e287.
93. Gong, D.W., Shuldiner, A.R., Yang, R.Z., Fried, S.K. Serum amyloid a protein in inflammation and obesity. US20090280108 (2009).
94. Kaser, M.R. Genes expressed in treated human C3A liver cell cultures. US6727066 (2004).
95. Ye, R.D., Cheng, N., He, R.L. Toll-like receptor agonists and antagonists and methods of use thereof. US7629135 (2009).
96. Baranova IN, Vishnyakova TG, Bocharov AV, Kurlander R, Chen Z, Kimelman ML, et al. Serum amyloid A binding to CLA-1 (CD36 and LIMPII analogous-1) mediates serum amyloid A protein-induced activation of ERK1/2 and p38 mitogen-activated protein kinases. J Biol Chem 2005; 280: 8031-40.
97. Bocharov, A.V., Patterson, A.L., Remaley, A.T., Vishnyakova, T.V., Baranova, I.N., Csako, G., Eggerman, T.L. Scavenger receptor B1 (CLA-1) targeting for the treatment of infection, sepsis and inflammation. US20090011974 (2009).
98. Wang, J.M., Oppenheim, J., Su, S.B., Gong, W.H., Gao, J.L., Murphy, P.M. Utilization of FPRL1 as a functional receptor by serum amyloid A (SAA). US20050085629 (2005).
99. McDonald, T.L., Weber, A. Serum amyloid A isoform from colostrum. US6509444 (2003).
100. McDonald, T.L., Larson, M.A., Weber, A. Genomic mammary Amyloid A sequence. US7214512 (2007).
101. McDonald, T.L., Weber, A. Diagnostic assays of secreted biological fluids for detection of infection and inflammatory conditions. US7569338 (2009).
102. McDonald, T.L., Larson, M.A, Weber, A. Human SAA3 nucleic acid molecule, protein, and methods of use for same. US7368546 (2008).
103. Plaizier, J.C., Krause, D.O. Diagnostic markers for sub-acute ruminal acidosis. US20070212741 (2007).
104. Meek RL, Eriksen N, Benditt EP. Murine serum amyloid A3 is a high density apolipoprotein and is secreted by macrophages. Proc Natl Acad Sci USA 1992; 89: 7949-52.
105. Kaufman, R.J., Zhang, K. Compositions and methods for modulating the acute phase response. US20070111258 (2007).
106. Freier, S.M. Antisense modulation of serum amyloid A4 expression. US6455308 (2002).
107. Hirano, N., Yamada, M. Monoclonal antibody recognizing serum amyloid A. US6375949 (2002).
108. McDonald TL, Weber A, Smith JW. A monoclonal antibody sandwich immunoassay for serum amyloid A (SAA) protein. J Immunol Methods 1991; 144: 149-55.
109. Wilkins J, Gallimore JR, Tennent GA, Hawkins PN, Limburg PC, van Rijswijk MH, et al. Rapid automated enzyme immunoassay of serum amyloid A. Clin Chem 1994; 40: 1284-90.
110. Yamada T, Kluve-Beckerman B, Kuster WM, Liepnieks JJ, Benson MD. Measurement of serum amyloid A4 (SAA4): Its constitutive presence in serum. Amyloid 1994;1: 114-8.
111. Pepys MB. Measurement of serum amyloid A protein concentrations as test of renal allograft rejection. Br Med J (Clin Res Ed) 1984; 288: 859-60.
112. Doyle, J.M., Hobson, H.A., Whitehead, A.S. Method for the quantitative measurement of human acute phase serum amyloid A protein; recombinant protein; specific antibody. US6194163 (2001).
113. Sipe, J.D., Knapschaefer, G., Gonnerman, W.A., Franzblau, C. Ligand/anti-ligand assays for adherent proteins. US5262303 (1993).
114. Sipe, J.D., Knapschaefer, G., Gonnerman, W.A., Franzblau, C. Ligand/anti-ligand assays for adherent proteins. US5536640 (1996).
115. Zuckerman SH, Surprenant YM. Simplified microELISA for the quantitation of murine serum amyloid A protein. J Immunol Methods 1986; 92:37-43.
116. Serban, D., Rordorf, C. Assay and purification of amyloid components, applications, and kits. US4782014 (1988).
117. Grubb, A.O., Ljunggren, L.W., Hansson, H.K. Peptide from amyloid A and antiserum. US4755380 (1988).
118. Shah, C., Hari-Dass, R., Raynes, J.G. Serum amyloid A is an innate immune opsonin for Gram negative bacteria. Blood 2006; 108: 1751-7.
119. Lavie M, Voisset C, Vu-Dac N, Zurawski V, Duverlie G, Wychowski C, et al. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 2006; 44: 1626-34.
120. Missé D, Yssel H, Trabattoni D, Oblet C, Lo Caputo S, Mazzotta F, et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 2007; 178: 407-15.